Hinge Health has released an impressive quarterly report, showing revenue and profit growth that has led to upgraded price targets from analysts.
Financial Achievements of Hinge Health
In its first quarterly report as a public company, Hinge Health reported revenue of $139.1 million, significantly exceeding consensus estimates of $125.4 million. This represents a robust 55% year-over-year growth from the $89.8 million recorded in Q2 2024. Profitability metrics were similarly strong, with a non-GAAP operating margin of 18.8%, far surpassing analyst expectations of just 3.1%.
Analyst Ratings and Perspectives
Following the earnings report, Citizens JMP Securities raised its price target on Hinge Health from $58 to $65 while maintaining its Market Outperform rating. Numerous other firms initiated coverage on Hinge Health after its May 2025 IPO, including Raymond James, which provided an outperform rating highlighting the company's potential for over 20% annual revenue growth over the next three years.
Future Outlook and Market Perspectives
Hinge Health forecasts revenue between $141 million and $143 million for Q3 2025, well above analyst expectations of $129 million. The company's full-year projection is between $548 million and $552 million, exceeding the anticipated $511 million. The anticipated launch of HingeSelect, a new provider network for musculoskeletal care, shows promise for further growth.
The combined achievements of Hinge Health in the recent quarter and positive outlooks from analysts indicate strong prospects for the company in the digital health market.
